STOCK TITAN

INVO BioScience,INC - INVO STOCK NEWS

Welcome to our dedicated page for INVO BioScience news (Ticker: INVO), a resource for investors and traders seeking the latest updates and insights on INVO BioScience stock.

About INVO BioScience, Inc. (Symbol: INVO)

INVO BioScience, Inc. is a pioneering healthcare services company dedicated to transforming the assisted reproductive technology (ART) landscape by making fertility care more accessible, inclusive, and affordable. At its core, the company combines innovative medical device technology with a comprehensive healthcare services model to address the unmet needs of individuals and couples seeking fertility treatment.

Core Technology: INVOcell® and Intravaginal Culture (IVC)

INVO BioScience's proprietary INVOcell® device represents a revolutionary advancement in fertility treatment. This first-of-its-kind medical device enables intravaginal culture (IVC), a technique where fertilization and early embryo development occur within the woman's body rather than in a laboratory setting. The IVC procedure offers a more natural, intimate, and cost-effective alternative to traditional in vitro fertilization (IVF) methods. By reducing the reliance on expensive laboratory infrastructure, the INVOcell® technology significantly lowers treatment costs, making advanced fertility care accessible to a broader demographic, including underserved populations.

Business Model and Operations

INVO BioScience operates through a hybrid business model encompassing:

  • INVO Centers: Dedicated fertility clinics focused on offering the INVOcell® and IVC procedures. These centers provide a streamlined, patient-centric experience, ensuring high-quality care at a fraction of the cost of traditional IVF treatments.
  • Clinic Acquisitions: The company strategically acquires profitable U.S.-based IVF clinics to expand its footprint and revenue base. These acquisitions complement its proprietary clinics, enabling INVO BioScience to capture a larger share of the fertility market.
  • Technology Distribution: INVOcell® devices are also distributed to existing fertility clinics, allowing them to integrate the IVC procedure into their service offerings.

Market Position and Differentiation

INVO BioScience operates within the growing global fertility market, which is driven by increasing infertility rates, delayed parenthood, and advancements in ART. The company's unique value proposition lies in its ability to offer a more affordable and natural fertility treatment option compared to traditional IVF. This positions INVO BioScience as a disruptor in the ART industry, targeting cost-conscious patients and regions with limited access to fertility care.

Unlike competitors that rely solely on traditional laboratory-based IVF methods, INVO BioScience differentiates itself through its innovative IVC approach and vertically integrated business model. This combination enables the company to control costs, improve patient outcomes, and expand its market reach.

Challenges and Industry Dynamics

As a disruptor in the ART space, INVO BioScience faces challenges such as educating the market about its novel IVC procedure, navigating complex regulatory environments, and competing with established IVF providers. However, its focus on affordability and accessibility aligns with broader healthcare trends, positioning the company to address significant gaps in the fertility market.

Recent Developments and Strategic Growth

INVO BioScience has recently expanded its scope through acquisitions and partnerships. The company's merger with NAYA Biosciences marks a strategic diversification into oncology and autoimmune therapeutics, leveraging shared resources to optimize growth. While fertility remains its core focus, this diversification reflects INVO BioScience's commitment to creating a scalable, multi-faceted healthcare platform.

Conclusion

INVO BioScience, Inc. stands at the forefront of innovation in fertility care, combining cutting-edge technology with a patient-first approach. Through its INVOcell® device, dedicated clinics, and strategic acquisitions, the company is redefining the ART marketplace, making advanced fertility treatments more accessible and affordable for individuals worldwide.

Rhea-AI Summary
INVO Bioscience, Inc. (Nasdaq: INVO) announced the solicitation of waivers from holders of the Company's common stock purchase warrants dated August 8, 2023, as a condition to the consummation of the proposed merger with NAYA Biosciences, Inc. The Waiver Solicitation is scheduled to expire on November 15, 2023. Important Additional Information will be filed with the SEC in connection with the Proposed Transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
90.68%
Tags
none
-
Rhea-AI Summary
NAYA Biosciences CEO Dr. Daniel Teper will present at Tribe Public's Webinar Presentation and Q&A Event on October 31, 2023. NAYA Biosciences aims to increase patient access to breakthrough treatments in oncology, regenerative medicine, and fertility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
none
-
Rhea-AI Summary
INVO Bioscience and NAYA Biosciences have entered into a definitive merger agreement for INVO to acquire NAYA in an all-stock transaction. The combined company will be named 'NAYA Biosciences' and will focus on increasing patient access to treatments in oncology, fertility, and regenerative medicine. The merger is valued at $12,373,780 for INVO and $90,750,000 for NAYA. NAYA Oncology has acquired two clinical-stage bispecific antibody assets for the treatment of Hepatocellular Carcinoma and Multiple Myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
292.59%
Tags
Rhea-AI Summary
INVO Bioscience CEO to participate in panel presentation at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
conferences
-
Rhea-AI Summary
INVO Bioscience, Inc. adjourns special meeting of shareholders to allow more time for voting on proposals. Proposal 1 to increase authorized shares has received affirmative vote of over 83% of shares casting votes. Proposal 2 to reduce exercise price for warrants has received affirmative vote of over 42% of shares casting votes. Shareholders encouraged to vote promptly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.94%
Tags
none
-
Rhea-AI Summary
INVO Bioscience reminds shareholders to vote ahead of the Special Meeting on September 29, 2023. Board unanimously recommends voting 'FOR' all proposals. Shareholders as of August 21, 2023, can vote. Increase in authorized shares and reduction in exercise price for warrants among matters to be voted on.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
Rhea-AI Summary
INVO Bioscience Announces Q2 2023 Financial Results and Business Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.68%
Tags
-
Rhea-AI Summary
INVO Bioscience, Inc. (Nasdaq: INVO) announces the acquisition of Wisconsin Fertility Institute, adding over $5 million in annual revenue, positive net income, and cash flows. The $10 million acquisition will enhance INVO's scale, operations, and commercial strategy, as well as complement its INVO Center strategy. The acquisition aligns with INVO's goal to democratize the fertility industry by leveraging its innovative INVOcell device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
-
Rhea-AI Summary
INVO Bioscience, Inc. (NASDAQ: INVO) to report financial results for its second quarter 2023 on August 14, 2023, after market close. The company will also conduct a conference call at 4:30 pm ET on the same day to review the results, offering interested parties call-in and webcast options for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
conferences earnings
Rhea-AI Summary
INVO Bioscience closes public offering, raising approximately $4.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags

FAQ

What is the current stock price of INVO BioScience (INVO)?

The current stock price of INVO BioScience (INVO) is $0.824 as of February 7, 2025.

What is the market cap of INVO BioScience (INVO)?

The market cap of INVO BioScience (INVO) is approximately 3.3M.

What is INVO BioScience's primary business focus?

INVO BioScience focuses on making fertility care more accessible and affordable through its proprietary INVOcell® device and intravaginal culture (IVC) procedure.

How does the INVOcell® device differ from traditional IVF methods?

The INVOcell® device enables fertilization and early embryo development within the woman's body, reducing costs and offering a more natural and intimate experience compared to traditional laboratory-based IVF.

What is the significance of INVO Centers?

INVO Centers are dedicated clinics that specialize in offering the INVOcell® and IVC procedures, providing cost-effective and high-quality fertility care to patients.

How does INVO BioScience generate revenue?

The company generates revenue through its INVO Centers, acquisitions of profitable IVF clinics, and the sale and distribution of its INVOcell® device to existing fertility clinics.

What challenges does INVO BioScience face in the fertility market?

Challenges include educating the market about its innovative IVC procedure, competing with established IVF providers, and navigating complex healthcare regulations.

What is the impact of the NAYA Biosciences merger on INVO BioScience?

The merger diversifies INVO BioScience's portfolio, expanding its focus into oncology and autoimmune therapeutics while maintaining its core fertility business.

What makes the IVC procedure more affordable than traditional IVF?

The IVC procedure reduces reliance on expensive laboratory infrastructure by enabling fertilization and embryo development within the woman's body, significantly lowering treatment costs.

What is the competitive advantage of INVO BioScience?

INVO BioScience's competitive advantage lies in its innovative IVC technology, cost-effective treatment options, and vertically integrated business model combining clinics and device distribution.
INVO BioScience,INC

Nasdaq:INVO

INVO Rankings

INVO Stock Data

3.25M
3.91M
0.63%
3.1%
0.05%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SARASOTA